T-cells are a key arm of the adaptive immune system and can function as therapeutic targets or treatments. EditCo, a pioneer of made-to-order cells, is the first to offer both CD4+ or CD8+ edited T-cells with guaranteed knockout efficiencies greater than 80% at a 14-day turnaround time.
In this webinar, EditCo's R&D team summarized the manufacturing process and highlight critical post-edit performance data, including viability, expansion, and functional readouts. Together, these data demonstrate that the EditCo Bio platform can quickly edit CD4+ or CD8+ T-cells at various endogenous loci across multiple donors preserving cell viability, expansion, and functionality.
Our speakers, Dr. Paolo Piazza and John Latimer, also covered:
- EditCo Bio’s edited pools of primary T-cells with guaranteed editing efficiency of over 80% in just 14 days.
- Options for editing from prescreened EditCo-supplied donors or your own T-cells.
- High cell viability and functionality in EditCo’s T-cell products with superior editing levels.
About the Speakers:
Dr. Paolo Piazza, Senior Scientist
Dr. Paolo Piazza is a Senior Scientist with 20+ years of expertise in immunology and virology. He specializes in T cell immune regulation, dendritic cell biology, and genome editing. With experience in both industry and academia, Dr. Piazza has co-authored publications about HIV, WNV, DENV, and ZIKV and successfully brought products to market.
.png?width=153&height=153&name=unnamed%20(3).png)
John Latimer, Director of Emerging Applications
John Latimer is the Director of Emerging Applications at EditCo Bio. John is responsible for the launch of new product types, including EditCo's recently launched T-cell product line. His prior experience in the industry includes Corporate Development roles at Synthego and CareDx after getting his start at Health Advances as a healthcare consultant.